US OptionsDetailed Quotes
PFE250103C17000
- 9.78
- 0.000.00%
15min DelayClose Jan 3 16:00 ET
0.00High0.00Low
0.00Open9.78Pre Close0 Volume0 Open Interest17.00Strike Price0.00Turnover0.00%IV-0.41%PremiumJan 3, 2025Expiry Date9.89Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.75Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Pfizer Stock Discussion
Sign in to post a comment
$Pfizer (PFE.US)$
The stock has broken the 26.83 resistance. Next hit point will be 27.15.
The stock has broken the 26.83 resistance. Next hit point will be 27.15.
4
2
$Pfizer (PFE.US)$
Malaysia saw 327 cases of human metapneumovirus (HMPV) infections in 2024, a 45 per cent rise from the 225 cases in 2023.
The Health Ministry said on Jan 4 that HMPV – a respiratory tract infection caused by a virus in the Pneumoviridae family – is not a new disease.
Those with HMPV typically experience symptoms similar to those of a common cold, but in more severe cases the symptoms can progress to bronchitis or pneumonia.
Malaysia recorded 327 HMPV cases in 2024; Health Ministry urges public to remain vigilant | The Straits Times
Malaysia saw 327 cases of human metapneumovirus (HMPV) infections in 2024, a 45 per cent rise from the 225 cases in 2023.
The Health Ministry said on Jan 4 that HMPV – a respiratory tract infection caused by a virus in the Pneumoviridae family – is not a new disease.
Those with HMPV typically experience symptoms similar to those of a common cold, but in more severe cases the symptoms can progress to bronchitis or pneumonia.
Malaysia recorded 327 HMPV cases in 2024; Health Ministry urges public to remain vigilant | The Straits Times
2
$Pfizer (PFE.US)$
Updates with response from Bristol-Myers Squibb in the fourth and fifth paragraphs.
Drugmakers including Pfizer (PFE), Bristol-Myers Squibb (BMY) and Sanofi (SNY) plan to raise US list prices on at least 250 branded medications, including COVID-19 treatments, cancer cell therapies and vaccines, at the start of 2025, Reuters reported Tuesday, citing data from the healthcare research firm 3 Axis Advisors.
Most of the price hikes are below 10% and are to list prices, which do not i...
Updates with response from Bristol-Myers Squibb in the fourth and fifth paragraphs.
Drugmakers including Pfizer (PFE), Bristol-Myers Squibb (BMY) and Sanofi (SNY) plan to raise US list prices on at least 250 branded medications, including COVID-19 treatments, cancer cell therapies and vaccines, at the start of 2025, Reuters reported Tuesday, citing data from the healthcare research firm 3 Axis Advisors.
Most of the price hikes are below 10% and are to list prices, which do not i...
2
4
$Pfizer (PFE.US)$ i bought 100 shares
2
1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
1
$Pfizer (PFE.US)$
Atavistik Bio Has Entered Into A Research Collaboration With Pfizer For Precision Allosteric Therapeutics, Leveraging Atavistik Bio's Platform To Identify And Validate Allosteric Binders Against Two Undisclosed, Pfizer-designated Targets, Financial Terms Were Not Disclosed.
Atavistik Bio Has Entered Into A Research Collaboration With Pfizer For Precision Allosteric Therapeutics, Leveraging Atavistik Bio's Platform To Identify And Validate Allosteric Binders Against Two Undisclosed, Pfizer-designated Targets, Financial Terms Were Not Disclosed.
The trading year ended with markets declining
Shortly after close, the $S&P 500 Index (.SPX.US)$ dipped 0.43% to 5,881.63, the $Dow Jones Industrial Average (.DJI.US)$ edged down 0.07% to 42,544.22, and the $Nasdaq Composite Index (.IXIC.US)$ dropped 0.9% to 19,310.79.
For the year, the Nasdaq Composite led the way, rising 29%. The S&P 500 was up 23% (a second straight year of 20% gains) and the Dow added almost 13%.
MACR...
Shortly after close, the $S&P 500 Index (.SPX.US)$ dipped 0.43% to 5,881.63, the $Dow Jones Industrial Average (.DJI.US)$ edged down 0.07% to 42,544.22, and the $Nasdaq Composite Index (.IXIC.US)$ dropped 0.9% to 19,310.79.
For the year, the Nasdaq Composite led the way, rising 29%. The S&P 500 was up 23% (a second straight year of 20% gains) and the Dow added almost 13%.
MACR...
60
6
8
$Pfizer (PFE.US)$ 🔥🔥🚀🚀🚀🚀🚀🚀🚀
2
1
No comment yet
RenenoMirai : Hit like 27.25, maybe going back to the “Fair valuation”
Deep Sea OP RenenoMirai : Yup. Soon will rise back to 30 level. Slow and steady rise.